<DOC>
	<DOCNO>NCT00446173</DOCNO>
	<brief_summary>Primary Objective : 1 . To study ex-vivo purge autologous hematopoietic stem cell use support high-dose chemotherapy patient chronic myelogenous leukemia ( CML ) . Major endpoint neutrophil engraftment survival . Secondary Objectives : 1 . To evaluate toxicity ex-vivo purge autologous cell use support high-dose chemotherapy . 2 . To evaluate rate duration cytogenetic remission achieve strategy . 3 . To determine time platelet recovery 20,000/mm3 . 4 . To determine one-year survival rate .</brief_summary>
	<brief_title>Autologous Stem Cell Transplants Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>Before treatment start , complete physical exam . You 4 tablespoon blood drawn test check status disease , check organ function , check infectious disease ( hepatitis , HIV , etc. ) . You sample bone marrow collect . To collect bone marrow sample , area hip chest bone numb anaesthetic small amount bone marrow withdrawn large needle . You also heart ( cardiac ejection fraction ) lung function test . All test do make sure eligible treatment . In order access blood circulation , silicone catheter ( small plastic tube ) place collar bone area . You local anesthesia procedure . If find eligible take part study , catheter use collection stem cell , infusion chemotherapy , fluid , electrolyte , medication , also blood sample lab test . It remain body length treatment ( 2-5 month ) . Normally , stem cell blood . The majority bone marrow . To help move `` mobilize '' cell need bone marrow blood , give chemotherapy follow injection skin day drug call G-CSF another drug call GM-CSF . These injection give 7-21 day . The injection may give nurse hospital , outpatient setting , may learn give . The chemotherapy receive help mobilize stem cell cyclophosphamide . It give vein hour one day . This first step toward collect stem cell necessary transplantation later . It separate high-dose chemotherapy get transplant . Blood sample ( 4 teaspoon ) draw day cyclophosphamide check number stem cell blood monitor possible side effect . If number stem cell blood high enough , go UTMDACC Apheresis Unit peripheral blood progenitor cell ( PBPC , stem cell ) collect . The procedure collect cell call leukapheresis . It similar donate platelet blood bank . The cell remove blood catheter remain blood give back catheter . This procedure perform machine process blood separate cell need transplantation , give rest back . Each leukapheresis procedure take 4-6 hour . You one leukapheresis procedure day , 1 5 day row , enough stem cell collect transplant `` '' back-up '' case problem treat cell . If 5 procedure , number cell collect low , additional collection cell may need . Some people may able enough cell collect blood . If case , may need bone marrow stem cell collect . You take operate room multiple collection bone marrow perform . The procedure perform general anesthesia . About 1 - 1.5 liter bone marrow collect . You ask donate blood procedure possible . That blood give back operating room . Somebody else 's blood may give instead donate . After enough stem cell collect , cell treat laboratory , use Gleevec ( imatinib mesylate ) follow ex vivo culture/purging . Culture-purging method take advantage fact CML cell die kept laboratory culture short time period normal blood cell . If cell keep alive long enough , survive cell less contaminated CML cell . Imatinib mesylate provide chemical way kill CML cell , since toxic CML cell normal cell . The culture-purging also use three medication call `` growth factor '' . The medication use stem cell factor , G-CSF , thrombopoietin . Busulfan cyclophosphamide chemotherapy drug design kill leukemia cell . However , combination kill significant amount bone marrow cell , basically stop production blood component . In order restart production , cell remove treated lab give back ( autologous transplant ) . You admit hospital receive high dose chemotherapy . You give busulfan continuous injection ( use catheter ) 4 day , give cyclophosphamide continuous injection ( use catheter ) 2 day . You may also receive antibiotic , fluid , medication doctor feels necessary . After receive chemotherapy , give treat bone marrow blood stem cell back . To help speed recovery white blood cell , also give G-CSF injection skin day white blood count recover ( usually 2 3 week ) GM-CSF skin month . You may also receive antibiotic , fluid , medication doctor feels necessary . Blood test ( 4 teaspoon ) repeat several time per week blood count fully recover side effect high dose therapy resolve . You check-up visit 1 , 3 , 6 , 12 month transplant . At visit , bone marrow sample collect monitor disease response . Bone marrow sample may also collect research time point . These sample use determine survival stem cell laboratory condition transplant . You blood collect ( 1- 4 tablespoon ) routine blood test . This investigational study . Busulfan , cyclophosphamide , G-CSF GM-CSF commercially available drug . Up 48 patient take part study . All treat M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients Philadelphia ( Ph ) chromosome positive CML &lt; age 65 old 21 year . Ph positive CML either : 1. late 1st chronic phase ( &gt; 2 year diagnosis ) 2. early chronic phase achieve complete cytogenetic remission one year imatinib 3. beyond first chronic phase 4. accelerate phase 5. blastic phase respond therapy ( characterize presence &lt; 10 % bone marrow and/or circulate blast consent signing ) 6. chronic phase , develop imatinib resistance ( loss molecular remission define least 1 log increase BCRABL/ABL ratio , 2 time point least 1 month apart , loss cytogenetic remission ) Patients must Zubrod PS &lt; 3 . Creatinine &lt; 1.8 mg/dl Serum bilirubin &lt; /= 1.5 mg/dl Serum glutamate pyruvate transaminase ( SGPT ) &lt; 3 x normal value Patients HLA identical sibling eligible refuse allogeneic transplantation , ineligible allogeneic transplantation due age . DLCO &gt; /= 50 % predict Cardiac Ejection fraction &gt; /= 40 % Uncontrolled lifethreatening infection comorbid condition could impair tolerance regimen . HIV positivity . Pregnant lactating woman . CML blastic phase respond therapy give prior enrollment study ( characterize presence 9 % bone marrow and/or peripheral blood blast time consent sign ) Hepatitis B C virus infection . Hepatitis B infection define positive DNA test , positive E / surface antigen . CML first molecular remission .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Philadelphia ( Ph ) chromosome positive CML</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
</DOC>